Table 1. MIC values (μg/mL) of compounds against a panel of bacteria.
| Compounda | Sa1c | Sa2c | MRSAc | MRSEc | Pac | Kpc | Abc |
|---|---|---|---|---|---|---|---|
| 1 | 6.8 ± 0.6 | >100 | 38.5 ± 4.3 | 31.5 ± 3.7 | >100 | 62.8 ± 4.0 | 63.2 ± 6.3 |
| 2 | 4.7 ± 0.6 | 84.1 ± 9.9 | 65.8 ± 3.9 | 65.7 ± 6.0 | 35.8 ± 4.5 | >100 | >100 |
| 3 | 5.5 ± 0.4 | 3.1 ± 0.3 | 29.3 ± 2.3 | 31.3 ± 3.4 | 8.0 ± 0.6 | 59.1 ± 5.1 | 60.1 ± 4.2 |
| 5 | 13.3 ± 1.5 | >100 | 62.5 ± 5.3 | >100 | >100 | >100 | >100 |
| 6 | 10.6 ± 0.4 | 40.2 ± 0.9 | >100 | >100 | 19.3 ± 0.6 | >100 | >100 |
| penicillinb | 0.5 ± 0.05 | 71.2 ± 6.0 | |||||
| streptomycinb | 0.6 ± 0.03 | ||||||
| tigecyclineb | 0.5 ± 0.03 | 0.7 ± 0.04 | 0.5 ± 0.05 | 0.6 ± 0.03 |
aThe compounds were inactive when MICs > 100 μg/mL, ±SD values were calculated on three individual experiments.
bPositive control.
cSa1, Staphylococcus aureus ATCC 25923; Sa2, S. aureus clinical strain; Pa, Pseudomonas aeruginosa ATCC 9027; Kp, Klebsiella pneumonia clinical strain; Ab, Acinetobacter baumannii clinical strain.